Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy
Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy
复制标题
DOI：
10.1200/jco.2000.18.10.2143
复制
发表时间：
2000-05-01
影响因子：
45.3
通讯作者：
Dantzer, R
中科院分区：
文献类型：
--
作者：
Capuron, L;Ravaud, A;Dantzer, R
目的：肿瘤患者的抑郁症常与白细胞介素（IL）-2和干扰素α-2b（INF α-2b）治疗有关。本研究的目的是评估肿瘤患者在细胞因子免疫治疗的第一天由IL-2和/或INF α-2b诱导的抑郁和焦虑症状，患者和方法：本研究包括48例肾细胞癌或黑色素瘤患者，患者接受皮下IL-2单独治疗（n = 20）或与INF α-2b联合治疗（n = 6）;或与单独的INF α-2b，以低剂量皮下给药（n = 8）或以高剂量皮下给药（n = 14）。采用蒙哥马利和阿斯伯格抑郁量表（MADRS）评估抑郁症状，采用Covi量表评估焦虑症状。评估进行之前开始的治疗（第1天），并在第3天和第5天的treatment.Results：用IL-2单独或与INF α-2b联合治疗的患者有显着较高的MADRS评分后5天的细胞因子治疗，谁收到两种细胞因子的患者在第3天的评分增加。相比之下，仅接受INF α-2b治疗的患者在治疗过程中没有不同的MADRS评分。细胞因子治疗对焦虑没有影响，除了IL-2联合INF α-2b治疗的患者。在这些患者中，在第5天观察到的焦虑评分的增强主要是由于增加躯体complaints. Conclusion：IL-2和INF α-2b对情绪有不同的影响，IL-2治疗诱导抑郁症状的早期治疗。J Clin Oncol 18：2143 - 2157. (C)2000年，美国临床肿瘤学会。
Purpose: Depressive symptomatology is frequently associated with interleukin (IL)-2 and interferon alfa-2b (INF alpha-2b) therapy in cancer patients. The objective of the present study was to evaluate the depressive and anxiety symptoms induced by IL-2 and/or INF alpha-2b in cancer patients during the first days of cytokine immunotherapy.Patients and Methods: The study included 48 patients with renal cell carcinoma or melanoma, Patients were treated either with subcutaneous IL-2, alone (n = 20) or in combination with INF alpha-2b (n = 6); or with INF alpha-2b alone, administered subcutaneously at a low dose (n = 8) or inf ravenously at a high dose (n = 14). Depressive symptoms were evaluated using the Montgomery and Asberg Depression Rating Scale (MADRS), and anxiety symptoms were evaluated using the Covi scale. Evaluations were performed just before initiation of treatment (day 1) and on days 3 and 5 of treatment.Results: Patients treated with IL-2 alone or in association with INF alpha-2b had significantly higher MADRS scores after 5 days of cytokine therapy, and patients who received both cytokines had increased scores on day 3. In contrast patients treated with INF alpha-2b alone did not have varying MADRS scores during the course of treatment. Cytokine therapy had no effect on anxiety, except in patients treated with IL-2 in combination with INF alpha-2b. In these patients, the enhancement in anxiety scores that was observed on day 5 was mainly attributable to increased somatic complaints.Conclusion: IL-2 and INF alpha-2b have differential effects on mood, and IL-2 therapy induces depressive symptoms early in treatment. J Clin Oncol 18:2143-2157. (C) 2000 by American Society of Clinical Oncology.